fenofibrate (Rx)

Brand and Other Names:Tricor, Lofibra tablets, more...Fenoglide, Lipofen, Triglide
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

TriCor tablet

  • 48mg
  • 145mg

Lofibra tablet

  • 54mg
  • 160mg

Fenoglide tablet

  • 40mg
  • 120mg

Triglide tablet

  • 160mg

Lipofen capsule

  • 50mg
  • 150mg

TriCor

Hypercholesterolemia, mixed dyslipidemia: Initially, 145 mg PO qDay

Hypertriglyceridemia: Initially, 48-145 mg PO qDay

Titrate q4-8week up to no more than 145 mg PO qDay

Triglide

Hypercholesterolemia, Mixed Dyslipidemia: initial 160 mg PO qDay

Hypertriglyceridemia: 50-160 mg PO qDay initially

Lipofen

Hypercholesterolemia, Mixed Dyslipidemia: initial 150 mg PO qDay

Hypertriglyceridemia: initial 50-150 mg PO qDay

Lofibra tablets

Hypercholesterolemia, Mixed Dyslipidemia: 160 mg PO qDay

Hypertriglyceridemia: 54-160 mg PO qDay

Fenoglide

Hypercholesterolemia, Mixed Dyslipidemia: 120 mg PO qDay

Hypertriglyceridemia: 40-120 mg PO qDay

Dosing Considerations

Overdose management

  • Symptoms include GI distress
  • Treatment is supportive

Dosing Modifications

Renal impairment

  • TriCor (CrCl <50 mL/min): 48 mg/day initially; evaluate before increase dose
  • Triglide: Initial, 50 mg/day
  • Lipofen: Initial, no more than 50 mg/day
  • Lofibra tablets: Initial, 54 mg/day
  • Fenoglide: Initial, 40 mg/day

Administration

TriCor, Triglide, and Lofibra tablets can be taken without regard to meals

Lipofen: Take with meals

Safety and efficacy not established

TriCor

Hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia

Initial: 48 mg/day; evaluate before increase dose

Triglide

Hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia

Initial: 50 mg/day

Lipofen

Hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia

Initial: No more than 50 mg/day

Lofibra tablets

Hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia

Initial: 54 mg/day

Fenoglide

Hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia

Initial: 40 mg/day

Next:

Interactions

Interaction Checker

and fenofibrate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (15)

              • abametapir

                abametapir will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.

              • apalutamide

                apalutamide will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.

              • atorvastatin

                fenofibrate, atorvastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

              • colchicine

                colchicine, fenofibrate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of rhabdomyolysis (incl a fatality).

              • fexinidazole

                fexinidazole will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.

              • fluvastatin

                fenofibrate, fluvastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

              • idelalisib

                idelalisib will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates

              • lovastatin

                fenofibrate, lovastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs. Do not exceed 20 mg/day of lovastatin.

              • pitavastatin

                fenofibrate, pitavastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

              • pravastatin

                fenofibrate, pravastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

              • rosuvastatin

                fenofibrate, rosuvastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

              • simvastatin

                fenofibrate, simvastatin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Fenofibrate may further increase risk for rhabdomyolysis when added to optimal statin regimen to further decrease TG and increase HDLs.

              • tucatinib

                tucatinib will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.

              • voxelotor

                voxelotor will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.

              • warfarin

                fenofibrate increases effects of warfarin by pharmacodynamic synergism. Avoid or Use Alternate Drug.

                fenofibrate increases effects of warfarin by plasma protein binding competition. Avoid or Use Alternate Drug.

              Monitor Closely (36)

              • belzutifan

                belzutifan will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information.

              • cannabidiol

                cannabidiol will increase the level or effect of fenofibrate by Other (see comment). Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit UGT1A9 activity. Consider reducing the dose when concomitantly using UGT1A9 substrates.

              • cenobamate

                cenobamate will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.

              • chlorpropamide

                fenofibrate increases effects of chlorpropamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • cholestyramine

                cholestyramine decreases levels of fenofibrate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              • cholic acid

                fenofibrate increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin.

              • crofelemer

                crofelemer increases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.

              • cyclosporine

                fenofibrate increases levels of cyclosporine by unspecified interaction mechanism. Use Caution/Monitor.

              • dabrafenib

                dabrafenib will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.

              • elagolix

                elagolix decreases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.

              • elvitegravir/cobicistat/emtricitabine/tenofovir DF

                elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.

              • fedratinib

                fedratinib will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.

              • fosphenytoin

                fosphenytoin will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • glimepiride

                fenofibrate increases effects of glimepiride by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • glipizide

                fenofibrate increases effects of glipizide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • glyburide

                fenofibrate increases effects of glyburide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • iloperidone

                iloperidone increases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.

              • insulin aspart

                fenofibrate increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • insulin degludec

                fenofibrate, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.

              • insulin degludec/insulin aspart

                fenofibrate, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.

              • insulin detemir

                fenofibrate increases effects of insulin detemir by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • insulin glargine

                fenofibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • insulin glulisine

                fenofibrate increases effects of insulin glulisine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • insulin inhaled

                fenofibrate, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.

              • insulin lispro

                fenofibrate increases effects of insulin lispro by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • insulin NPH

                fenofibrate increases effects of insulin NPH by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • insulin regular human

                fenofibrate increases effects of insulin regular human by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • istradefylline

                istradefylline will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.

              • mitotane

                mitotane decreases levels of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.

              • rucaparib

                rucaparib will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.

              • stiripentol

                stiripentol, fenofibrate. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.

              • tazemetostat

                tazemetostat will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              • tecovirimat

                tecovirimat will decrease the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.

              • tenofovir DF

                fenofibrate increases levels of tenofovir DF by decreasing renal clearance. Use Caution/Monitor. Increased risk of myopathy.

              • tolazamide

                fenofibrate increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              • tolbutamide

                fenofibrate increases effects of tolbutamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

              Minor (4)

              • colestipol

                colestipol decreases levels of fenofibrate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • ezetimibe

                fenofibrate increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown.

              • octacosanol

                octacosanol increases effects of fenofibrate by pharmacodynamic synergism. Minor/Significance Unknown.

              • ribociclib

                ribociclib will increase the level or effect of fenofibrate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              >10%

              Increased LFT's (dose related, 3-13%)

              1-10%

              Respiratory disorder (6%)

              Abdominal pain (5%)

              Back pain (3%)

              CPK increased (3%)

              Headache (3%)

              Constipation (2%)

              Nausea (2%)

              Rhinitis (2%)

              Postmarketing Reports

              Muscle pain

              Myopathies

              Myositis

              Diarrhea

              Flatulence

              Pancreatitis

              Peptic ulcer

              Cholelithiasis

              CNS depression

              Dysrhythmias

              Peripheral vascular disease

              Pulmonary embolus

              Renal damage

              Rash

              Anemia

              Leukopenia

              Previous
              Next:

              Warnings

              Contraindications

              Known hypersensitivity

              Severe renal impairment, including those with end-stage renal disease and those receiving dialysis

              Active liver disease

              Gallbladder disease

              Nursing mothers

              Cautions

              Cholelithiasis reported with use; discontinue if gallstones detected upon gallbladder studies

              Rare myopathy, myositis, or rhabdomyolysis reported with use; monitor

              Increase in hepatic transaminases reported; discontinue if enzyme levels persist 3 times above the upper limit of normal

              Reversibly increases serum creatinine levels; consider monitoring renal function in patients at risk for renal impairment

              Thrombocytopenia and agranulocytosis reported; monitor blood counts periodically during the first year of therapy

              Associated with pulmonary embolism and deep venous thrombosis; use caution in patients with risk factors for VTE

              Concomitant use with oral anticoagulants (monitor and adjust warfarin dose prn)

              May further increase risk for rhabdomyolysis when added to optimal HMG-CoA reductase inhibitor regimen to further decrease TG and increase HDLs

              Paradoxical decreases in HDL cholesterol (HDL-C) level reported

              Rule out secondary causes of hyperlipidemia before initiating therapy

              Withdraw therapy if no adequate response seen after 2-3 months

              Use with caution in the elderly; dose adjustments may be necessary

              Fenofibrate increases cholesterol excretion into bile, leading to risk of cholelithiasis; perform gallbladder studies if cholelithiasis suspected

              Fibric acid derivatives as monotherapy or in combination with simvastatin have not been shown to significantly reduce cardiovascular mortality in major clinical studies

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

              Animal data

              • In animal reproduction studies, no evidence of embryo-fetal toxicity was observed with oral administration in rats and rabbits during organogenesis at doses less than or equivalent to the maximum recommended clinical dose of 120 mg daily, based on body surface area (mg/m2)
              • Adverse reproductive outcomes occurred at higher doses in presence of maternal toxicity; drug should be used during pregnancy only if potential benefit justifies potential risk to fetus

              Lactation

              There is no available information on presence of drug in human milk, effects on the breastfed infant, or on milk production; drug is present in milk of rats, and likely to be present in human milk; because of potential for serious adverse reactions in breastfed infants, such as disruption of infant lipid metabolism, women should not breastfeed during treatment and for 5 days after final dose

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Increases VLDL catabolism, fatty acid oxidation, and elimination of triglyceride rich particles by enhancing synthesis of lipoprotein lipase, which in turn results in 30-60% decrease in total plasma triglycerides; HDL may increase modestly in some hypertriglyceridemic patients

              Absorption

              Bioavailability: 60-90%

              Onset: 2 wk

              Peak plasma time: 2-8 hr

              Distribution

              Distributes widely to most tissues

              Protein bound: 99%

              Metabolism

              Liver

              Metabolites: Fenofibric acid (active), fenofibric acid glucuronide (activity unknown)

              Elimination

              Half-life: 20 hr (10-35 hr range)

              Dialyzable: No (HD)

              Excretion: Urine (60-93%), feces (5-25%)

              Pharmacogenomics

              Genotyping patients with atherogenic dyslipidemia may establish who will benefit most from fenofibric acid therapy to increase HDL-C

              Three single-nucleotide polymorphisms (SNPs) in the APOA5 region have been associated with increases in HDL-C

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              120 mg tablet
              fenofibrate oral
              -
              40 mg tablet
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              fenofibrate oral
              -
              150 mg capsule
              fenofibrate oral
              -
              50 mg capsule
              fenofibrate oral
              -
              160 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              fenofibrate oral
              -
              54 mg tablet
              Lipofen oral
              -
              150 mg capsule
              Lipofen oral
              -
              50 mg capsule
              Fenoglide oral
              -
              40 mg tablet
              Fenoglide oral
              -
              120 mg tablet

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Patient Education
              fenofibrate oral

              FENOFIBRATE - ORAL

              (fen-oh-FYE-brate)

              COMMON BRAND NAME(S): Tricor, Triglide

              USES: Fenofibrate is used along with a proper diet to help lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. It works by increasing the natural substance (enzyme) that breaks down fats in the blood. Fenofibrate belongs to a group of drugs known as "fibrates." Lowering triglycerides in people with very high triglyceride blood levels may decrease the risk of pancreas disease (pancreatitis). However, fenofibrate might not lower your risk of a heart attack or stroke. Talk to your doctor about the risks and benefits of fenofibrate.In addition to eating a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details.

              HOW TO USE: Take this medication by mouth as directed by your doctor, usually once daily. Fenofibrate comes in different types of capsules and tablets which provide different amounts of the medication. Do not switch between different forms or brands of this medication unless directed by your doctor. Some forms of this drug should be taken with food but others may be taken with or without food. Ask your pharmacist about your brand of fenofibrate. It is important to take this medication correctly so that the drug has the greatest benefit.The dosage is based on your medical condition and response to treatment.If you are also taking certain other drugs to lower your cholesterol (bile acid-binding resins such as cholestyramine or colestipol), take fenofibrate at least 1 hour before or at least 4 to 6 hours after taking these medications. These medications can bind to fenofibrate, preventing your body from fully absorbing the drug.Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. Do not increase your dose or use this drug more often or for longer than prescribed. Your cholesterol/triglycerides level will not lower faster, and your risk of side effects will increase. Keep taking this medication even if you feel well. Most people with high cholesterol/triglycerides do not feel sick.It is very important to continue to follow your doctor's advice about diet and exercise. It may take up to 2 months before you get the full benefit of this medication.

              SIDE EFFECTS: Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.This medication may rarely cause gallstones and liver problems. If you notice any of the following unlikely but serious side effects, tell your doctor right away: nausea/vomiting that doesn't stop, loss of appetite, stomach/abdominal pain, yellowing eyes/skin, dark urine.This drug may rarely cause muscle problems (which can rarely lead to a very serious condition called rhabdomyolysis). Tell your doctor right away if you develop any of these symptoms: muscle pain/tenderness/weakness (especially with fever or unusual tiredness), signs of kidney problems (such as change in the amount of urine).Rarely, this medication has caused severe lowering of HDL ("good" cholesterol) levels. This is the opposite of what should happen to your HDL levels (paradoxical reaction). Your HDL cholesterol levels should be checked regularly. Keep all of your laboratory appointments.Tell your doctor right away if you have any serious side effects, including: easy bleeding/bruising, unusual tiredness.Get medical help right away if you have any very serious side effects, including: chest pain, sudden pain/redness/swelling usually in the leg, signs of infection (such as sore throat that doesn't go away, fever, swollen lymph nodes, chills, cough).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before taking fenofibrate, tell your doctor or pharmacist if you are allergic to it; or to other "fibrates" (such as fenofibric acid); or if you have any other allergies. This product may contain inactive ingredients (such as soy), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, gallbladder disease, liver disease (such as biliary cholangitis, hepatitis), alcohol use.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Because of the possible risk to the infant, breast-feeding is not recommended while using this drug and for 5 days after stopping the drug. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: See also How to Use section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: "blood thinners" (such as warfarin).Fenofibrate is very similar to fenofibric acid. Do not use medications containing fenofibric acid while using fenofibrate.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

              NOTES: Do not share this medication with others.Laboratory and/or medical tests (such as cholesterol/triglyceride levels, kidney/liver function tests, complete blood count) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details. (See also Side Effects section.)

              MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from light and moisture. Different brands of this medication have different storage needs. Check the product package for instructions on how to store your brand, or ask your pharmacist. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.